Last update:

Medications news

Medical research

Researcher calls for one-person trials for personalized medicine

"All things are poison, and nothing is without poison, the dosage alone makes it so a thing is not a poison." These were the words of Paracelsus, a Swiss physician who recognized back in the 16th century that every medicine ...

Medications

A new method of action for an older anti-diabetic drug discovered

A research team led by Kobe University Graduate School of Medicine's Professor OGAWA Wataru (the Division of Diabetes and Endocrinology) and Project Associate Professor NOGAMI Munenobu (the Department of Radiology) has discovered ...

Medications

Long-term rituximab may aid in antibody-associated vasculitis

For patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), extended therapy with rituximab is associated with a reduced incidence of antineutrophil cytoplasmic antibody-associated vasculitis ...

Medications

What are the risks and benefits of low-dose aspirin?

Low-dose aspirin significantly lowers cardiovascular disease risk but increases the risk of bleeding, according to a review published in the British Journal of Clinical Pharmacology.

Medications

Study shows hydroxychloroquine's harmful effects on heart rhythm

The malaria drug hydroxychloroquine, which has been promoted as a potential treatment for COVID-19, is known to have potentially serious effects on heart rhythms. Now, a team of researchers has used an optical mapping system ...

Medications

Remdesivir use growing globally in COVID-19 patients

Worldwide more physicians are using remdesivir to treat COVID-19 patients, according to a survey released May 21 by Sermo, a global health care polling company and social platform for physicians.

Medications

Scientists raise concern over hydroxychloroquine study

Dozens of scientists have raised concerns over a large-scale study of hydroxychloroquine and chloroquine published in the Lancet that led to the World Health Organization suspending clinical trials of the anti-viral drugs ...

Medications

Five-day course of remdesivir beneficial in severe COVID-19

(HealthDay)—There seems to be no significant difference between a five- and 10-day course of remdesivir for patients with severe COVID-19 not requiring mechanical ventilation, according to a study published online May 27 ...

Medications

Relugolix superior to leuprolide in advanced prostate cancer

(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is ...

Medications

Immunotherapy for bowel cancer could change clinical practice

A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the 'progression free survival' time of ...